Журнал «» Том 16, №3-4, 2023
Вернуться к номеру
Маскована гіпертензія як фактор високого ризику серцево-судинних захворювань і смертності
Авторы: Скибчик В.А. (1), Пилипів О.С. (2)
(1) — Львівський національний медичний університет імені Данила Галицького, м. Львів, Україна
(2) — КП «Центральна міська лікарня Червоноградської міської ради», м. Червоноград, Україна
Рубрики: Кардиология
Разделы: Справочник специалиста
Версия для печати
Резюме
Маскована гіпертензія (МГ) є одним з фенотипів артеріального тиску з високим ризиком прогресування до стійкої гіпертензії і тотожним ризиком серцево-судинних захворювань і смертності. Саме тому потенційно важливо не пропустити діагноз маскованої гіпертензії і вчасно запобігти можливим несприятливим ефектам, які пов’язані з нею. У статті узагальнено дані щодо визначення, діагностики, факторів ризику, клінічних наслідків і лікування маскованої гіпертензії.
Masked hypertension is one of the blood pressure phenotypes with a high risk of progressing to sustained hypertension with comparable cardiovascular and mortality risk. That is why it is potentially important not to miss the diagnosis of masked hypertension and timely prevent possible adverse effects. This review summarizes current data on definition, screening, risk factors, clinical implications and treatment of masked hypertension.
Ключевые слова
маскована гіпертензія; серцево-судинний ризик; амбулаторне моніторування артеріального тиску; домашнє моніторування артеріального тиску
masked hypertension; cardiovascular risk; ambulatory blood pressure monitoring; home blood pressure monitoring
Для ознакомления с полным содержанием статьи необходимо оформить подписку на журнал.
Список литературы
1. Pickering T.G., Davidson K., Gerin W., Schwartz J.E. Masked hypertension. Hypertension. 2002. 40(6). 79a5-6.
2. Bobrie G., Clerson P., Ménard J. et al. Masked hypertension: a systematic review. J. Hypertens. 2008. 26(9). 1715-25.
3. Aksoy I., Deinum J., Lenders J.W., Thien T. Does masked hypertension exist in healthy volunteers and apparently well-controlled hypertensive patients? Neth. J. Med. 2006. 64(3). 72-7.
4. Yano Y., Bakris G.L. Recognition and management of masked hypertension: a review and novel approach. J. Am. Soc. Hypertens. 2013 May. 7(3). 24-52.
5. National Institute for Health and Care Excellence [NICE]. Hypertension in adults: diagnosis and management. NICE guideline [NG136]. London: National Institute for Health and Care Excellence. 2019. [cited 2019 Nov 20]. https://www.nice.org.uk/guidance/ng136/ chapter/recommendations.
6. Williams B., Mancia G., Spiering W. et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur. Heart J. 2018. 39(33). 3021-104.
7. de la Sierra A., Vinyoles E., Banegas J.R. et al. Short-term and long-term reproducibility of hypertension phenotypes obtained by office and ambulatory blood pressure measurements. J. Clin. Hypertens. 2016. 18(9). 927-33.
8. Roerecke M., Kaczorowski J., Myers M.G. Comparing auto–mated office blood pressure readings with other methods of blood pressure measurement for identifying patients with possible hypertension: a systematic review and meta-analysis. JAMA Intern. Med. 2019. 179(3). 351-62.
9. Kayrak M., Bacaksiz A., Vatankulu M.A. et al. Exagge-rated blood pressure response to exercise — a new portent of masked hypertension. Clin. Exp. Hypertens. 2010. 32(8). 560-8.
10. Ugajin T., Hozawa A., Ohkubo T. et al. White-coat hypertension as a risk factor for the development of home hypertension: the Ohasama study. Arch. Intern. Med. 2005. 165(13). 1541-6.
11. Trudel X., Brisson C., Gilbert-Ouimet M. et al. Masked hypertension incidence and risk factors in a prospective cohort study. Eur. J. Prev. Cardiol. 2019. 26(3). 231-7.
12. Parati G., Ochoa J.E. White-Coat and Masked Hypertension. In: Bakris G.L., Sorrentino M.J., editors. Hypertension: a companion to Braunwald’s Heart Disease. 3rd ed. Philadelphia: Elsevier. 2018. Р. 104-14.
13. Thakkar H.V., Pope A., Anpalahan M. Masked hypertension: a systematic review. Heart Lung. Circ. 2020. 29(1). 102-11.
14. Xavier T., Brisson C., Gilbert-Ouimet M. et al. Masked hypertension incidence: risk factors in a prospective cohort study. J. Hypertens. 2018. 36 (Suppl. 1). e2.
15. Sivén S.S.E., Niiranen T.J., Kantola I.M., Jula A.M. White-coat and masked hypertension as risk factors for progression to sustained hypertension: the Finn-Home study. J. Hypertens. 2016. 34(1). 54-60.
16. Fujiwara T., Yano Y., Hoshide S., Kanegae H., Kario K. Association of cardiovascular outcomes with masked hypertension defined by home blood pressure monitoring in a japanese general practice population. JAMA Cardiol. 2018. 3(7). 583-90.
17. Tientcheu D., Ayers C., Das S.R. et al. Target organ complications and cardiovascular events associated with masked hypertension and white-coat hypertension: analysis from the Dallas Heart Study. J. Am. Coll. Cardiol. 2015. 66(20). 2159-69.
18. National Institute for Health and Care Excellence. Hypertension: clinical management of primary hypertension in adults (update). https://www.nice.org.uk/guidance/cg127/chapter/1-guidance. Accessed December 2016.
19. Sharman J.E., Howes F.S., Head G.A. et al. Home blood pressure monitoring: Australian Expert Consensus Statement. J. Hypertens. 2015. 33. 1721-1728. doi: 10.1097/HJH.0000000000000673.
20. Siu A.L.; U.S. Preventive Services Task Force. Screening for high blood pressure in adults: U.S. Preventive Services Task Force recommendation statement. Ann. Intern. Med. 2015. 163. 778-786. doi: 10.7326/ M15-2223.
21. Zhang L., Li Y., Wei F.F., Thijs L. et al. Strategies for classifying patients based on office, home, and ambulatory blood pressure measurement. Hypertension. 2015. 65. 1258-1265. doi: 10.1161/HYPERTENSIONAHA.114.05038.
22. Stergiou G.S., Salgami E.V., Tzamouranis D.G., Roussias L.G. Masked hypertension assessed by ambulatory blood pressure versus home blood pressure monitoring: is it the same phenomenon? Am. J. Hypertens. 2005. 18. 772-778. doi: 10.1016/j.amjhyper.2005.01.003.
23. Franklin S.S., O’Brien E., Thijs L. et al. Masked hypertension: a phenomenon of measurement. Hypertension. 2015. 65. 16-20. doi: 10.1161/HYPERTENSIONAHA.114.04522.
24. Diaz K.M., Veerabhadrappa P., Brown M.D. et al. Prevalence, determinants, and clinical significance of masked hypertension in a population-based sample of African Americans: the Jackson Heart study. Am. J. Hypertens. 2015. 28. 900-908. doi: 10.1093/ajh/hpu241.
25. Piper M.A., Evans C.V., Burda B.U. et al. Diagnostic and predictive accuracy of blood pressure screening methods with consideration of rescreening intervals: a systematic review for the U.S. Preventive Services Task Force. Ann. Intern. Med. 2015. 162. 192-204. doi: 10.7326/M14-1539
26. de la Sierra A., Banegas J.R., Vinyoles E. et al. Prevalence of masked hypertension in untreated and treated patients with office blood pressure below 130/80 mm Hg. Circulation. 2018. 137. 2651-2653.
27. Trudel X., Milot A., Brisson C. Persistence and progression of masked hypertension: a 5-year prospective study. Int. J. Hypertens. 2013. 2013. 836387. doi: 10.1155/2013/836387.
28. Fagard R.H., Cornelissen V.A. Incidence of cardiovascular events in white-coat, masked and sustained hypertension versus true normotension: a meta-analysis. J. Hypertens. 2007. 25. 2193-2198. doi: 10.1097/HJH.0b013e3282ef6185.
29. Palla M., Saber H., Konda S., Briasoulis A. Masked hypertension and cardiovascular outcomes: an updated systematic review and meta-analysis. Integr. Blood Press. Control. 2018. 11. 11-24. doi: 10.2147/ IBPC.S128947.
30. Pierdomenico S.D., Pierdomenico A.M., Coccina F. et al. Prognostic value of masked uncontrolled hypertension. Hypertension. 2018. 72(4). 862-9.
31. Fujiwara T., Yano Y., Hoshide S., Kanegae H., Kario K. Association of cardiovascular outcomes with masked hypertension defined by home blood pressure monitoring in a Japanese general practice population. JAMA Cardiol. 2018. 3. 583-590. doi: 10.1001/jamacardio.2018.123360.
32. Satoh M., Asayama K., Kikuya M. et al. Long-term stroke risk due to partial white-coat or masked hypertension based on home and ambulatory blood pressure measurements: the Ohasama study. Hypertension. 2016. 67. 48-55. doi: 10.1161/HYPERTENSIONAHA.115.06461.
33. Sega R., Trocino G., Lanzarotti A. et al. Alterations of cardiac structure in patients with isolated office, ambulatory, or home hypertension: data from the general population (Pressione Arteriose Monitorate E Loro Associazioni [PAMELA] Study). Circulation. 2001. 104. 1385-1392.
34. Sekoba N.P., Kruger R., Labuschagne P., Schutte A.E. Left ventricular mass independently associates with masked hypertension in young healthy adults: the African-PREDICT study. J. Hypertens. 2018. 36. 1689-1696. doi: 10.1097/HJH.0000000000001740.
35. Hoshide S., Yano Y., Kanegae H., Kario K. Effect of lo-wering home blood pressure on subclinical cardiovascular disease in masked uncontrolled hypertension. J. Am. Coll. Cardiol. 2018. 71. 2858-2859. doi: 10.1016/j.jacc.2018.04.017.
36. Bromfield S.G., Shimbo D., Booth J.N. 3rd et al. Cardiovascular risk factors and masked hypertension: the Jackson Heart Study. Hypertension. 2016. 68. 1475-1482. doi: 10.1161/HYPERTENSIONAHA.116.08308.
37. Wald D.S., Law M., Morris J.K. et al. Combination the-rapy versus monotherapy in reducing blood pressure: meta-ana-lysis on 11,000 participants from 42 trials. Am. J. Med. 2009. 122. 290-300. doi: 10.1016/j.amjmed.2008.09.038.
38. Franklin S.S., O’Brien E., Staessen J.A. Masked hypertension: understanding its complexity. Eur. Heart J. 2017. 38. 1112-1118. doi: 10.1093/eurheartj/ehw502.
39. Franklin S.S.,. O’Brien E., Thijs L. et al. Masked hypertension: a phenomenon of measurement. Hypertension. 2015. 65. 16-20. doi: 10.1161/HYPERTENSIONAHA.114.04522.
40. Banegas J.R., Ruilope L.M., de la Sierra A. et al. Relationship between clinic and ambulatory blood-pressure measurements and mortality. N. Engl. J. Med. 2018. 378. 1509-1520. doi: 10.1056/NEJMoa1712231.
41. Wojciechowska W., Stolarz-Skrzypek K., Olszanecka A. et al. Subclinical arterial and cardiac damage in white-coat and masked hypertension. Blood Press. 2016. 25. 249-256. doi: 10.3109/08037051. 2016.1150563.
42. Hata J., Fukuhara M., Sakata S. et al. White-coat and masked hypertension are associated with albuminuria in a general population: the Hisayama Study. Hypertens. Res. 2017. 40. 937-943. doi: 10.1038/hr.2017.74.
43. Tientcheu D., Ayers C., Das S.R. et al. Target organ complications and cardiovascular events associated with masked hypertension and white-coat hypertension: analysis from the Dallas Heart Study. J. Am. Coll. Cardiol. 2015. 66. 2159-2169. doi: 10.1016/j.jacc.2015.09.007
44. Anstey D.E., Muntner P., Bello N.A., et al. Diagnosing Masked Hypertension Using Ambulatory Blood Pressure Monitoring, Home Blood Pressure Monitoring, or Both? Hypertension. 2018 Nov. 72(5). 1200-7.
45. Tocci G., Presta V., Figliuzzi I. et al. Prevalence and clinical outcomes of white-coat and masked hypertension: analysis of a large ambulatory blood pressure database. J. Clin. Hypertens. (Greenwich). 2018. 20. 297-305. doi: 10.1111/jch.13181.
46. Mancia G., Kreutz R., Brunström M. et al. 2023 ESH. Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension Endorsed by the European Renal Association (ERA) and the International Society of Hypertension (ISH). Journal of Hypertension. June 21, 2023. DOI: 10.1097/HJH.0000000000003480.